Tisotumab Vedotin for Metastatic Cervical Cancer: Results From ESMO 2023 With Brian Slomovitz, MD
In this interview, Dr. Brian Slomovitz, Director …
Oncology Data Advisor · i3 Health
November 1, 20235m 8s
Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this interview, Dr. Brian Slomovitz, Director of Gynecologic Oncology at Mount Sinai Medical Center in Miami Beach, Florida, shares the results of the innovaTV 301 trial of tisotumab vedotin for patients with recurrent or metastatic cervical cancer, which were recently presented at the European Society for Medical Oncology (ESMO) 2023 Congress.